AU701578B2 - Immunoglobulins devoid of light chains - Google Patents

Immunoglobulins devoid of light chains Download PDF

Info

Publication number
AU701578B2
AU701578B2 AU49497/93A AU4949793A AU701578B2 AU 701578 B2 AU701578 B2 AU 701578B2 AU 49497/93 A AU49497/93 A AU 49497/93A AU 4949793 A AU4949793 A AU 4949793A AU 701578 B2 AU701578 B2 AU 701578B2
Authority
AU
Australia
Prior art keywords
immunoglobulin
immunoglobulins
cells
domain
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49497/93A
Other languages
English (en)
Other versions
AU4949793A (en
Inventor
Cecile Casterman
Raymond Hamers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Original Assignee
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26132410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU701578(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP92402326A external-priority patent/EP0584421A1/en
Application filed by Vrije Universiteit Brussel VUB, Universite Libre de Bruxelles ULB filed Critical Vrije Universiteit Brussel VUB
Publication of AU4949793A publication Critical patent/AU4949793A/en
Assigned to VRIJE UNIVERSITEIT BRUSSEL reassignment VRIJE UNIVERSITEIT BRUSSEL Alteration of Name(s) of Applicant(s) under S113 Assignors: CASTERMAN, CECILE, HAMERS, RAYMOND
Priority to AU98131/98A priority Critical patent/AU738133B2/en
Application granted granted Critical
Publication of AU701578B2 publication Critical patent/AU701578B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU49497/93A 1992-08-21 1993-08-18 Immunoglobulins devoid of light chains Ceased AU701578B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU98131/98A AU738133B2 (en) 1992-08-21 1998-12-23 Immunoglobulins devoid of light chains

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP92402326A EP0584421A1 (en) 1992-08-21 1992-08-21 Immunoglobulins devoid of light chains
EP92402326 1992-08-21
EP93401310 1993-05-21
EP93401310 1993-05-21
PCT/EP1993/002214 WO1994004678A1 (en) 1992-08-21 1993-08-18 Immunoglobulins devoid of light chains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU98131/98A Division AU738133B2 (en) 1992-08-21 1998-12-23 Immunoglobulins devoid of light chains

Publications (2)

Publication Number Publication Date
AU4949793A AU4949793A (en) 1994-03-15
AU701578B2 true AU701578B2 (en) 1999-02-04

Family

ID=26132410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49497/93A Ceased AU701578B2 (en) 1992-08-21 1993-08-18 Immunoglobulins devoid of light chains

Country Status (13)

Country Link
US (5) US6015695A (enExample)
EP (6) EP2192131A1 (enExample)
JP (4) JP3444885B2 (enExample)
AT (5) ATE203767T1 (enExample)
AU (1) AU701578B2 (enExample)
CA (1) CA2142331C (enExample)
DE (6) DE69330523T4 (enExample)
DK (5) DK0656946T4 (enExample)
ES (5) ES2338321T3 (enExample)
FI (3) FI115462B (enExample)
GR (1) GR3037024T3 (enExample)
PT (5) PT656946E (enExample)
WO (1) WO1994004678A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide

Families Citing this family (1330)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0937140T3 (da) * 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
EP0931097B1 (en) * 1996-10-10 2005-09-14 Neose Technologies, Inc. Carbohydrate purification using reverse osmosis and nanofiltration
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
AU3596599A (en) * 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
DE69920897T2 (de) * 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
WO2001007555A1 (en) 1999-07-27 2001-02-01 Unilever N.V. Bleaching detergent compositions
DE60019309T2 (de) * 1999-09-16 2005-09-22 Unilever Plc Abgabesystem für ein mittel gegen schuppen
US6479280B1 (en) * 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1088892A1 (en) * 1999-09-24 2001-04-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ATE342922T1 (de) 1999-11-29 2006-11-15 Unilever Nv Immobilisierung von proteinen mit hilfe eines polypeptidsegments
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
WO2002057445A1 (en) * 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US7858559B2 (en) * 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20060064782A1 (en) * 2000-12-18 2006-03-23 Conopco, Inc. Production of antibodies
BR0116283A (pt) 2000-12-19 2005-12-13 Unilever Nv Grânulo de anticorpo, composições detergente, enzimática alvejante de manchas e enzimática de anti-transferência de corante, e, processo para a preparação de um grânulo de anticorpo
CA2447832C (en) * 2000-12-22 2012-09-25 Jamshid Tanha Phage display libraries of human vh fragments
US20030021766A1 (en) 2001-01-12 2003-01-30 Michael Vajdy Nucleic acid mucosal immunization
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050069538A1 (en) * 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040086508A1 (en) * 2001-06-05 2004-05-06 Advanced Biotherapy, Inc. Treatment of organ transplant rejection
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) * 2001-06-05 2005-07-14 Advanced Biotherapy, Inc. Treatment of diabetic retinopathy
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2003054016A2 (en) * 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
EP1461085A2 (en) * 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
CA2472927A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
CN101653603B (zh) 2002-07-15 2014-07-09 得克萨斯大学体系董事会 磷脂酰乙醇胺结合肽缀合物及其治疗病毒感染的用途
WO2004015425A1 (en) 2002-08-07 2004-02-19 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
GB0219720D0 (en) * 2002-08-23 2002-10-02 Univ Aberdeen Polypeptide
US20040052790A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
KR20050092029A (ko) 2003-01-10 2005-09-16 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
EP1437764A1 (en) * 2003-01-10 2004-07-14 S.O.I. Tec Silicon on Insulator Technologies S.A. A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
CA2534661A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
EP1687452A4 (en) * 2003-09-30 2008-08-06 Centocor Inc HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF
US20050112130A1 (en) 2003-11-05 2005-05-26 Bhat Neelima M. Enhanced B cell cytotoxicity of CDIM binding antibody
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005105984A2 (en) * 2004-04-12 2005-11-10 The Trustees Of The University Of Pennsylvania Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
CN1942203A (zh) * 2004-06-04 2007-04-04 金克克国际有限公司 使用抗体重链的筛选方法
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
DK1776383T3 (da) 2004-07-22 2014-11-03 Kingdon Craig R Bindingsmolekyler
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
US20060177445A1 (en) * 2004-08-16 2006-08-10 Boris Skurkovich Treatment of inflammatory skin diseases
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
US7462454B2 (en) * 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
ATE473446T1 (de) 2005-01-14 2010-07-15 Ablynx Nv Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
CA2595682A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2520669A3 (en) 2005-02-07 2013-02-27 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
DK1863849T3 (da) * 2005-03-11 2011-08-08 Syngenta Ltd Bekæmpelse af gnavere
EP3144675A1 (en) 2005-04-28 2017-03-22 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
WO2006116742A2 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
CN101296706B (zh) 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
WO2007036022A1 (en) * 2005-09-27 2007-04-05 National Research Council Of Canada Targeted delivery of compounds using multimerization technology
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7526409B2 (en) * 2005-10-07 2009-04-28 Oracle International Corporation Automatic performance statistical comparison between two periods
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
DK1951316T3 (en) * 2005-11-23 2015-08-31 Ventana Med Syst Inc molecular conjugate
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
CA2640066A1 (en) * 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
US20080070268A1 (en) * 2006-04-21 2008-03-20 Wyeth Differential expression profiling analysis of cell culture phenotypes and the uses thereof
CA2649932A1 (en) 2006-05-02 2007-11-15 Actogenix Nv Microbial intestinal delivery of obesity related peptides
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
WO2007147090A2 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
BRPI0714212B8 (pt) 2006-07-13 2021-05-25 Wyeth Corp método de produzir uma glicoproteína em uma cultura celular
EP2292663B1 (en) 2006-08-28 2013-10-02 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
WO2008044928A1 (en) 2006-10-10 2008-04-17 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
DK2444807T3 (da) 2006-11-01 2014-08-11 Ventana Med Syst Inc Mono- og dinitropyrazolhaptenkonjugater
EP2092080A1 (en) 2006-11-07 2009-08-26 Vib Vzw Diagnosis and treatment of t-cell acute lymphoblastic leukemia
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US20080267949A1 (en) * 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
CA2678218A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
PT2426144T (pt) 2007-02-23 2019-02-06 Merck Sharp & Dohme Anticorpos anti-il-23p19 fabricados por engenharia genética
NZ597915A (en) 2007-02-28 2013-08-30 Merck Sharp & Dohme Combination therapy for treatment of immune disorders
EP2057194B1 (en) 2007-02-28 2013-03-20 Merck Sharp & Dohme Corp. Engineered anti-il-23r antibodies
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
PT2164868E (pt) 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
MX2009012341A (es) 2007-05-14 2010-02-17 Medimmune Llc Metodos para reducir niveles de eosinofilos.
WO2008153744A2 (en) 2007-05-23 2008-12-18 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20090017460A1 (en) * 2007-06-15 2009-01-15 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
WO2009004066A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
WO2009012181A2 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Method of identifying diagnostic reagents
EP2170960B1 (en) 2007-07-13 2015-07-29 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian igg
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
EA201000718A1 (ru) 2007-11-02 2011-06-30 Новартис Аг Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
JP5514399B2 (ja) * 2007-11-02 2014-06-04 国立大学法人 岡山大学 無機硫黄化合物加水分解酵素の製造方法
WO2010008411A1 (en) 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
KR20100097716A (ko) * 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
WO2009086215A2 (en) * 2007-12-21 2009-07-09 Wyeth Pathway analysis of cell culture phenotypes and uses thereof
JP5889533B2 (ja) 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
CA2720013C (en) 2008-04-03 2016-02-16 Bart De Strooper Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP3173424A1 (en) 2008-05-02 2017-05-31 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
DK2995925T3 (da) 2008-06-05 2022-02-21 Ventana Med Syst Inc Sammensætning til histokemisk processering
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
TW201336510A (zh) 2008-07-18 2013-09-16 必治妥美雅史谷比公司 結合ｃｄ２８之單價組合物及其使用方法
US9034325B2 (en) 2008-07-22 2015-05-19 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
JP5815403B2 (ja) 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
EP2344180A2 (en) 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
WO2010077422A2 (en) 2008-10-29 2010-07-08 Wyeth Llc Formulations of single domain antigen binding molecules
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
US9260508B2 (en) 2008-12-19 2016-02-16 Ablynx N.V. Method for generation of immunoglobulin sequences
CN102257131A (zh) 2008-12-19 2011-11-23 先灵公司 用于哺乳动物细胞培养的给料添加剂及使用方法
US20110311515A1 (en) 2009-01-14 2011-12-22 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
EP2394159B1 (en) 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2230515B1 (en) 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivation of surfaces after ligand coupling
EP2411125B1 (en) 2009-03-24 2019-05-08 Wyeth LLC Membrane evaporation for generating highly concentrated protein therapeutics
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
KR20130119990A (ko) 2009-04-10 2013-11-01 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
BRPI1016055A2 (pt) 2009-04-27 2016-05-10 Novartis Ag composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
CA2759370C (en) 2009-04-30 2020-02-11 Peter Schotte Method for the production of domain antibodies
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
DK2438087T3 (en) 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
WO2011012646A2 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
US8563694B2 (en) 2009-07-31 2013-10-22 Medarex, Inc. Fully human antibodies to BTLA
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
HUE049825T2 (hu) 2009-09-03 2020-10-28 Merck Sharp & Dohme Anti-GITR antitestek
JP5962996B2 (ja) 2009-09-03 2016-08-03 キャンサー・リサーチ・テクノロジー・リミテッド Ｃｌｅｃ１４ａ阻害剤
PT2473527T (pt) 2009-09-03 2017-02-27 Ablynx NV Formulações estáveis de polipéptidos e seus usos
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110117113A1 (en) 2009-10-09 2011-05-19 Gerald Beste Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
EP2491056B1 (en) 2009-10-22 2021-09-15 Universiteit Twente Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
WO2011050242A1 (en) 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
MY162511A (en) 2009-11-04 2017-06-15 Merck Sharp & Dohme Engineered anti-tslp antibody
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
SI2954779T1 (sl) 2009-12-10 2019-06-28 Regeneron Pharmaceuticals, Inc. Miši, ki proizvajajo težkoverižna protitelesa
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
ES2931330T3 (es) 2010-02-11 2022-12-28 Ablynx Nv Métodos y composiciones para la preparación de aerosoles
DK2539355T3 (da) 2010-02-26 2017-01-02 Ventana Med Syst Inc IN-SITU-hybridisering med polytag-prober
CA2788275A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
AU2011231558B2 (en) 2010-03-26 2016-08-11 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
CN102939004B (zh) 2010-04-06 2015-09-23 阿格罗塞文公司 农用化学品的特异性输送
GB201105584D0 (en) 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
CA2796087A1 (en) 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
MX2012012736A (es) 2010-05-07 2013-02-26 Hoffmann La Roche Metodo de diagnostico para la deteccion de celulas ex vivo.
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
KR20130080790A (ko) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Ｈｅｒ３와 관련된 생물학적 물질들
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
JP2013531801A (ja) 2010-07-02 2013-08-08 ヴェンタナ メディカル システムズ， インク． 標的検出のためのハプテンコンジュゲート
AU2011273360A1 (en) 2010-07-02 2013-02-07 Vib Vzw The role of Fragile X mental retardation gene and protein in cancer metastasis
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN108314733A (zh) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
WO2012024185A1 (en) 2010-08-16 2012-02-23 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
PT2606070T (pt) 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2609116A1 (en) 2010-08-26 2013-07-03 Agrosavfe N.V. Insect binding antibodies
US9516879B2 (en) 2010-08-26 2016-12-13 Agrosavfe N.V. Chitinous polysaccharide antigen-binding proteins
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
HUE069364T2 (hu) 2010-10-29 2025-03-28 Ablynx Nv Eljárás immunglobulin variábilis egydomének elõállítására
GB201018602D0 (en) 2010-11-04 2010-12-22 Vib Vzw MMP8 inactivating antigen binding proteins
SG10201509145XA (en) 2010-11-05 2015-12-30 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
EA037063B1 (ru) 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2-связывающие полипептиды
WO2012084895A2 (en) 2010-12-20 2012-06-28 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
JP5815046B2 (ja) 2010-12-30 2015-11-17 ヴェンタナ メディカル システムズ， インク． ピリミジンアナログを用いた色素原の沈着増強
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
US9850315B2 (en) 2011-02-01 2017-12-26 Bac Ip B.V. Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
EP2683290B1 (en) 2011-03-07 2018-11-07 F.Hoffmann-La Roche Ag Methods for in vivo testing of therapeutic antibodies
CN103534359B (zh) 2011-03-14 2016-07-06 文塔纳医疗系统公司 分析染色体易位的方法及其系统
EP2686016B1 (en) 2011-03-14 2019-05-01 Cellmid Limited Antibody recognizing n-domain of midkine
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
AU2012234282B2 (en) 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
MX2013011092A (es) 2011-03-30 2013-12-06 Boehringer Ingelheim Int Antidotos anticoagulantes.
KR102031020B1 (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707382B1 (en) 2011-05-09 2019-07-17 Ablynx NV Method for the production of immunoglobulin single variable domains
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
RU2661677C2 (ru) 2011-05-27 2018-07-18 Аблинкс Нв Ингибирование резорбции кости с помощью связывающих rank-l пептидов
US9580480B2 (en) 2011-05-31 2017-02-28 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
JP6187777B2 (ja) 2011-06-13 2017-08-30 シーエスエル、リミテッド Ｇ−ｃｓｆｒに対する抗体およびその使用
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CA2839834A1 (en) 2011-06-21 2012-12-27 Vib Vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
IN2014CN00437A (enExample) 2011-06-23 2015-04-03 Ablynx Nv
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
WO2013033073A1 (en) 2011-08-31 2013-03-07 Ventana Medical Systems, Inc. Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
US20150158934A1 (en) 2011-09-09 2015-06-11 Ucl Business Plc Broadly neutralizing vhh against hiv-1
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
US20140235492A1 (en) 2011-09-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicate (Inserm) Methods for preparing single domain antibody microarrays
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EP2747783B1 (en) 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
US9127056B2 (en) 2011-10-17 2015-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9265817B2 (en) 2011-10-28 2016-02-23 Patrys Limited PAT-LM1 epitopes and methods for using same
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
UY34486A (es) 2011-12-05 2013-07-31 Novartis Ag Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
KR20200014441A (ko) 2012-01-20 2020-02-10 젠자임 코포레이션 항cxcr3 항체
WO2013113696A1 (en) 2012-01-30 2013-08-08 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
PH12021553014A1 (en) 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10041950B2 (en) 2012-03-27 2018-08-07 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
JP5970734B2 (ja) 2012-03-30 2016-08-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｎｇ２結合分子
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
ES2715279T3 (es) 2012-05-24 2019-06-03 Vib Vzw Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US20150164800A1 (en) 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EA201590709A1 (ru) 2012-10-09 2015-09-30 Байоджен Айдек Ма Инк. Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
LT2922962T (lt) 2012-11-20 2017-04-10 Novartis Ag Optimizuota raiškos kasetė, skirta polipeptido raiškai su didele išeiga
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
HRP20210517T1 (hr) 2012-12-05 2021-05-14 Novartis Ag Pripravci i postupci za protutijela usmjerena na epo
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
SG11201504676VA (en) 2012-12-14 2015-07-30 Omt Inc Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
CA2891686A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
SG11201504765VA (en) 2012-12-21 2015-07-30 Amplimmune Inc Anti-h7cr antibodies
CN112858672A (zh) 2013-01-30 2021-05-28 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
EP3590578A1 (en) 2013-02-05 2020-01-08 VIB vzw Muscarinic acetylcholine receptor binding agents and uses thereof
ES2942636T3 (es) 2013-02-07 2023-06-05 Csl Ltd Proteínas de unión a IL-11R y usos de las mismas
EP2953969B1 (en) 2013-02-08 2019-08-28 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
JP6416793B2 (ja) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
ES2804300T3 (es) 2013-03-12 2021-02-05 Ventana Med Syst Inc Microscopía mejorada digitalmente para histología multiplexada
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
AU2014229952B2 (en) 2013-03-15 2018-10-04 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
WO2014146575A1 (en) 2013-03-19 2014-09-25 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
ES2762151T3 (es) 2013-04-29 2020-05-22 Agrosavfe Nv Composiciones agroquímicas que comprenden anticuerpos que se unen esfingolípidos
WO2014183052A1 (en) 2013-05-09 2014-11-13 The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN106414489A (zh) 2013-05-24 2017-02-15 米迪缪尼有限公司 抗-b7-h5抗体及其用途
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
ES2698375T3 (es) 2013-06-27 2019-02-04 Inst Nat Sante Rech Med Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias
US20160176943A1 (en) 2013-07-05 2016-06-23 Inserm (Insititut National De La Sante Et De La Recherche Medicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
HK1219280A1 (zh) 2013-08-14 2017-03-31 Novartis Ag 治疗偶发性包涵体肌炎之方法
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
AU2014354588B2 (en) 2013-11-28 2020-07-02 B-Creative Sweden Ab Method of treating nephropathy
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
ES2851386T3 (es) 2013-12-18 2021-09-06 Csl Ltd Método de tratamiento de las heridas
US10640569B2 (en) 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015091914A2 (en) 2013-12-20 2015-06-25 Intervet International B.V. Caninized murine antibodies to human pd-1
WO2015100409A2 (en) 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10233241B2 (en) 2014-01-30 2019-03-19 Vib Vzw Opioid receptor binding agents and uses thereof
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2900749T3 (es) 2014-02-11 2022-03-18 Visterra Inc Moléculas de anticuerpos contra el virus del dengue y usos de las mismas
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
DK3134095T3 (da) 2014-04-25 2020-06-29 Bluebird Bio Inc Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
RU2708311C2 (ru) 2014-04-25 2019-12-05 Блубёрд Био, Инк. Химерные антигенные рецепторы с mnd-промотором
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
KR20180091115A (ko) 2014-05-16 2018-08-14 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016012363A1 (en) 2014-07-22 2016-01-28 Vib Vzw Methods to select for agents that stabilize protein complexes
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
MX356502B (es) 2014-07-29 2018-05-31 Univ Brussel Vrije Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
EA036311B1 (ru) 2014-08-19 2020-10-26 Мерк Шарп И Доум Корп. Антитела против tigit
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
KR102510540B1 (ko) 2014-10-03 2023-03-16 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SI3204095T1 (sl) 2014-10-10 2019-08-30 Ablynx N.V. Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom
CA2963037A1 (en) 2014-10-10 2016-04-14 Ablynx N.V. Treatment of rsv infection
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
AR102550A1 (es) 2014-11-05 2017-03-08 Agrosavfe Nv Planta transgénica que comprende un polinucleótido que codifica un dominio variable de anticuerpo de cadena pesada
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11001625B2 (en) 2014-12-10 2021-05-11 Tufts University VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
BR112017012344B1 (pt) 2014-12-11 2024-02-06 Pierre Fabre Medicament Anticorpo anti-c10orf54 ou fragmento de ligação ao antígeno do mesmo, conjugado anticorpo-fármaco, composição farmacêutica, kit, seus usos, polinucleotídeo, vetor de expressão e métodos de produção do anticorpo ou fragmento de ligação ao antígeno e de detecção c10orf54 em uma amostra
EP3640262A1 (en) 2014-12-12 2020-04-22 Bluebird Bio, Inc. Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
US11426468B2 (en) 2014-12-19 2022-08-30 Ablynx N.V. Cysteine linked nanobody dimers
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
CA2972597A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
CN107428813B (zh) 2014-12-31 2021-08-03 查克美特制药公司 组合肿瘤免疫疗法
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
EP3253791A1 (en) 2015-02-03 2017-12-13 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-rho gtpase conformational single domain antibodies and uses thereof
ES2777534T3 (es) 2015-02-13 2020-08-05 Inserm - Institut National De La Santé Et De La Rech Médicale Polipéptidos para la ingeniería de proteínas integrasas quiméricas y su uso en terapia génica
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
HUE061070T2 (hu) 2015-03-03 2023-05-28 Kymab Ltd Ellenanyagok, alkalmazások és eljárások
US11066480B2 (en) 2015-03-17 2021-07-20 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
ES2721781T3 (es) 2015-03-25 2019-08-05 Alexion Pharma Inc Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
EP3274724A1 (en) 2015-03-25 2018-01-31 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
ES2973042T3 (es) 2015-03-31 2024-06-18 Sorriso Pharmaceuticals Inc Polipéptidos
WO2016156466A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
CA2981103A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
US10273305B2 (en) 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
RU2736732C2 (ru) 2015-04-02 2020-11-19 Интервет Интернэшнл Б.В. Антитела к альфа-рецептору собачьего интерлейкина-4
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US10851176B2 (en) 2015-04-13 2020-12-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
US9778265B2 (en) 2015-04-16 2017-10-03 The United States Of America, As Represented By The Secretary Of The Navy Charged peptide appendage to facilitate oriented protein covalent immobilization
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
EP3294334B1 (en) 2015-05-11 2020-07-08 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
HUE045437T2 (hu) 2015-05-13 2019-12-30 Ablynx Nv TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
RS65904B1 (sr) 2015-05-13 2024-09-30 Ablynx Nv Polipeptidi koji regrutuju t ćelije na osnovu reaktivnosti cd3
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN107614014B (zh) 2015-05-28 2022-07-12 生物辐射实验室股份有限公司 亲和配体及其相关方法
EP3303394B1 (en) 2015-05-29 2020-04-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
TN2017000417A1 (en) 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3314260B1 (en) 2015-06-24 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017013026A1 (en) 2015-07-17 2017-01-26 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20190008983A1 (en) 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3331904B1 (en) 2015-08-07 2020-12-23 Merck Patent GmbH A transglutamine tag for efficient site-specific bioconjugation
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
SI3334763T1 (sl) 2015-08-11 2025-01-31 WuXi Biologics Ireland Limited Nova protitelesa proti pd-1
ES2911015T3 (es) 2015-08-31 2022-05-17 Helixmith Co Ltd Receptores quiméricos de antígeno anti-sialil Tn
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
NZ740067A (en) 2015-09-09 2021-07-30 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
CN105238759B (zh) * 2015-10-14 2019-05-24 吉日木图 抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
AU2016353073A1 (en) 2015-11-10 2018-06-07 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
NO2768984T3 (enExample) 2015-11-12 2018-06-09
EP3374389A1 (en) 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
CA3004900C (en) 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
SI3380522T1 (sl) 2015-11-25 2024-02-29 Visterra, Inc. Molekule protitelesa proti APRIL in uporabe le-teh
US10894834B2 (en) 2015-11-27 2021-01-19 Csl Limited CD131 binding proteins
SG11201803976VA (en) 2015-11-27 2018-06-28 Ablynx Nv Polypeptides inhibiting cd40l
TWI734719B (zh) 2015-12-04 2021-08-01 德商百靈佳殷格翰國際股份有限公司 在腫瘤細胞中拮抗ｗｎｔ信號傳遞之雙抗體結合部位（ｂｉｐａｒａｔｏｐｉｃ）多肽
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US10829562B2 (en) 2015-12-10 2020-11-10 Katholieke Universiteit Leuven Haemorrhagic disorder due to ventricular assist device
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP4541807A3 (en) 2015-12-18 2025-09-24 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
EP3397755B1 (en) 2015-12-28 2024-11-06 Novartis AG Methods of making chimeric antigen receptor -expressing cells
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
HK1257455A1 (zh) 2016-02-17 2019-10-18 Novartis Ag TGFβ2抗体
EP3423482A1 (en) 2016-03-04 2019-01-09 Novartis AG Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433281A1 (en) 2016-03-21 2019-01-30 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
WO2017161976A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW202302144A (zh) 2016-03-25 2023-01-16 美商威特拉公司 登革病毒的抗體分子之配方設計
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
EP3442993B1 (en) 2016-04-13 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
JP7125351B2 (ja) 2016-04-14 2022-08-24 ２セブンティ バイオ インコーポレイテッド サルベージキメラ抗原受容体システム
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
PL3443096T3 (pl) 2016-04-15 2023-06-19 Novartis Ag Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
WO2017184562A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
US11243214B2 (en) 2016-04-22 2022-02-08 Université Libre de Bruxelles Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
JP2019523213A (ja) 2016-05-02 2019-08-22 アブリンクス エン．ヴェー． Ｒｓｖ感染の処置
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
KR102419412B1 (ko) 2016-05-18 2022-07-12 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 항-pd1 및 항-lag3 항체
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
CA3024683A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
CN109475630A (zh) 2016-05-27 2019-03-15 瑞颂医药公司 治疗难治性全身型重症肌无力的方法
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2017223419A1 (en) 2016-06-24 2017-12-28 Ig Biosciences Corporation Prebiotic neutraceutical compositions and methods of treatment using the same
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
BR112019000630A2 (pt) 2016-07-13 2019-07-09 Biogen Ma Inc regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018017964A2 (en) 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom
TW202508628A (zh) 2016-07-28 2025-03-01 瑞士商諾華公司 嵌合抗原受體及pd-1抑制劑之組合療法
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
RU2019105693A (ru) 2016-08-01 2020-09-01 Новартис Аг Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
KR102777127B1 (ko) 2016-08-02 2025-03-07 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
BR112019002127A2 (pt) 2016-08-03 2019-09-17 Nextcure Inc proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
BR112019005292A2 (pt) 2016-09-21 2019-09-03 Nextcure, Inc. anticorpos para siglec-15 e métodos de uso dos mesmos.
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
EP3515948A4 (en) 2016-09-23 2020-04-08 CSL Limited COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
EP3515936A1 (en) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
NZ792355A (en) 2016-10-11 2025-12-19 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
JP7256741B2 (ja) 2016-10-12 2023-04-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
US11828683B2 (en) 2016-10-19 2023-11-28 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5a in a sample
US11965884B2 (en) 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
EP3950709B1 (en) 2016-10-21 2024-02-14 OSE Immunotherapeutics Methods for promoting t cells response
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
WO2018081578A1 (en) 2016-10-28 2018-05-03 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017355504C1 (en) 2016-11-04 2024-06-20 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
JP7222888B2 (ja) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
BR112019009904A2 (pt) 2016-11-17 2019-08-13 Bluebird Bio, Inc. conversor de sinal de tgfss
US11773163B2 (en) 2016-11-21 2023-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
JP2020513554A (ja) 2016-12-07 2020-05-14 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
SG10201912560YA (en) 2016-12-07 2020-02-27 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
TW201834711A (zh) 2016-12-14 2018-10-01 美商寶珍那提公司 以tnf抑制劑治療胃腸道疾病
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
AU2017378406A1 (en) 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
AU2017378398B2 (en) 2016-12-14 2023-02-02 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
CA3045475A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
US11820979B2 (en) 2016-12-23 2023-11-21 Visterra, Inc. Binding polypeptides and methods of making the same
EP3565560B1 (en) 2017-01-09 2024-05-29 OnkosXcel Therapeutics, LLC Predictive and diagnostic methods for prostate cancer
EP3571223B1 (en) 2017-01-18 2024-09-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP2020505037A (ja) 2017-01-19 2020-02-20 オープン モノクローナル テクノロジー，インコーポレイテッド 複数の重鎖免疫グロブリン遺伝子座を有するトランスジェニックげっ歯類由来のヒト抗体
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
LT3580237T (lt) 2017-02-08 2025-07-10 Novartis Ag Fgf21 antikūnų mimetikai ir jų panaudojimo būdai
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3054623A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
DE202018006693U1 (de) 2017-03-14 2022-03-08 Nanotag Biotechnologies Gmbh Target-Detektion mit einem monovalenten Antikörper
CN110753702B (zh) 2017-03-15 2022-09-20 清华大学 抗trkb抗体
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
PT3600415T (pt) 2017-03-24 2025-11-24 Novartis Ag Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca
EA201992278A1 (ru) 2017-03-27 2020-03-03 Селджин Корпорейшн Способы и композиции для снижения иммуногенности
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
EP3601531B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
AU2018249493A1 (en) 2017-04-03 2019-09-19 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
EP3612561A1 (en) 2017-04-19 2020-02-26 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
SG11201909751TA (en) 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11225514B2 (en) 2017-05-30 2022-01-18 The Regents Of The University Of California Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
HUE067691T2 (hu) 2017-05-31 2024-11-28 Boehringer Ingelheim Int A tumorsejtekben a Wnt jelátvitelt antagonizáló polipeptidek
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
WO2018220235A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
ES3002733T3 (en) 2017-06-02 2025-03-07 Merck Patent Gmbh Adamts binding immunoglobulins
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
KR20200013231A (ko) 2017-06-02 2020-02-06 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
EP3415010A1 (en) 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
KR102574549B1 (ko) 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
EP3645041A4 (en) 2017-06-28 2021-03-17 The Rockefeller University AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES
RU2019143078A (ru) 2017-06-28 2021-07-28 Новартис Аг Способы предупреждения и лечения недержания мочи
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
CN111278858B (zh) 2017-07-11 2024-07-23 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
US11155607B2 (en) 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
EP3658581A1 (en) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
EP4218813A3 (en) 2017-07-27 2023-08-16 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
CN111182951A (zh) 2017-08-01 2020-05-19 指南针制药有限责任公司 过滤和层析荚以及使用其的方法
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
CA3074647A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
AU2018328764B2 (en) 2017-09-11 2025-01-09 Monash University Binding proteins to the human thrombin receptor, PAR4
CN111655340A (zh) 2017-09-20 2020-09-11 国家医疗保健研究所 用于调节自噬的方法和药物组合物
MY205689A (en) 2017-10-02 2024-11-06 Visterra Inc Antibody molecules to cd138 and uses thereof
EP3461841B1 (en) 2017-10-02 2019-09-11 Certest Biotec, S.L. Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
MX2020004074A (es) 2017-10-19 2020-10-16 Debiopharm Int Sa Producto de combinacion para el tratamiento de cancer.
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200069358A (ko) 2017-10-25 2020-06-16 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
JP7760115B2 (ja) 2017-10-31 2025-10-27 フエー・イー・ベー・フエー・ゼツト・ウエー 新規抗原結合性キメラタンパク質とその方法及び使用
WO2019090148A2 (en) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111417406B (zh) 2017-11-29 2025-02-21 Csl有限公司 治疗或防止缺血-再灌注损伤的方法
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
JP2021505208A (ja) 2017-12-05 2021-02-18 セリアド エス．アー．Ｃｅｌｙａｄ Ｓ．Ａ． 養子細胞療法用細胞の持続性を向上するための組成物および方法
EP3720950B1 (en) 2017-12-05 2025-09-03 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
AU2018396970B2 (en) 2017-12-28 2025-09-25 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US20190330591A1 (en) 2018-01-10 2019-10-31 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
CA3264983A1 (en) 2018-01-15 2025-10-31 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
EP3740231A4 (en) 2018-01-18 2022-03-23 California Institute of Technology PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLS
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
KR20200112913A (ko) 2018-01-23 2020-10-05 넥스트큐어 인코포레이티드 B7-h4 항체 및 그 사용 방법
WO2019145413A1 (en) 2018-01-25 2019-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
US12180285B2 (en) 2018-02-01 2024-12-31 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
EP3749690A1 (en) 2018-02-05 2020-12-16 Stichting VU Inverse agonistic anti-us28 antibodies
AU2019215440B2 (en) 2018-02-05 2025-12-04 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
WO2019157191A1 (en) 2018-02-07 2019-08-15 Georgia Tech Research Corporation Methods for multiplexed cell isolation using dna gates
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
EP3758742A1 (en) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
CN117964751A (zh) 2018-03-13 2024-05-03 斯米维特公司 与破伤风神经毒素结合的单域抗体
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP4043496A1 (en) 2018-03-14 2022-08-17 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
WO2019179420A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
MX2020009879A (es) 2018-03-22 2021-01-08 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
WO2019185723A1 (en) 2018-03-27 2019-10-03 Umc Utrecht Holding B.V. Targeted thrombolysis for treatment of microvascular thrombosis
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
US20210047696A1 (en) 2018-03-28 2021-02-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US20190345261A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
EP3790898A4 (en) 2018-05-10 2022-03-02 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019226617A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
WO2019241685A1 (en) 2018-06-14 2019-12-19 Bluebird Bio, Inc. Cd79a chimeric antigen receptors
CA3102036A1 (en) 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
JP7332194B2 (ja) 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
MX2021000165A (es) 2018-07-11 2021-05-28 Actym Therapeutics Inc Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
EA202190243A1 (ru) 2018-07-11 2021-06-16 Селджин Корпорейшн Применение химерных антигенных рецепторов к bcma
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
US12485126B2 (en) 2018-07-19 2025-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
ES2738926A1 (es) 2018-07-26 2020-01-27 Univ Zaragoza Granulisina, metodo de obtencion y usos
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
TW202538050A (zh) 2018-08-31 2025-10-01 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
EP3844180A4 (en) 2018-08-31 2022-07-20 California Institute of Technology Synthetic protein circuits detecting signal transducer activity
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3848397A4 (en) 2018-09-04 2022-07-20 Nanjing Umab-Biopharma Co., Ltd. Fusion protein and its application in preparing medicine for treating tumor and/or viral infection
GB201814451D0 (en) 2018-09-05 2018-10-17 Valerie Nicholas Carl Kristoffer Methods
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3849996A1 (en) 2018-09-11 2021-07-21 NanoTag Biotechnologies GmbH Epitope tags recognized by specific binders
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
ES2974217T3 (es) 2018-10-30 2024-06-26 Alexion Pharma Inc Posología subcutánea y administración de anticuerpos anti-C5 para el tratamiento de hemoglobinuria paroxística nocturna (HPN)
WO2020089273A1 (en) 2018-10-31 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating t-helper type 2 mediated disease
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
EP3894438A1 (en) 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
WO2020123011A1 (en) 2018-12-13 2020-06-18 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
WO2020128892A1 (en) 2018-12-20 2020-06-25 Novartis Ag Extended low dose regimens for mdm2 inhibitors
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
CN113574067A (zh) 2018-12-21 2021-10-29 Ose免疫疗法公司 双功能抗PD-1/SIRPα分子
KR20210107058A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 인간 pd-1에 대항하는 이작용성 분자
EP3906260A4 (en) 2019-01-02 2022-08-31 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5 AND METHOD OF USE THEREOF
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
CN113490686B (zh) 2019-01-07 2025-02-18 拜科托莱夫股份有限公司 病原体结合蛋白
EP3908653A4 (en) 2019-01-10 2022-11-02 California Institute of Technology A synthetic system for tunable thresholding of protein signals
US12466866B2 (en) 2019-01-15 2025-11-11 INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Paris, FRANCE Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
KR20210131312A (ko) 2019-01-16 2021-11-02 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 항체의 제제 및 이의 용도
US20220119516A1 (en) 2019-01-16 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
TWI756621B (zh) 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020169707A1 (en) 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
JP7737306B2 (ja) 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN114127113A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与钙网蛋白结合的多功能分子及其用途
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
ES2984072T3 (es) 2019-03-08 2024-10-28 Linxis B V Moléculas de unión internalizantes que actúan sobre receptores implicados en la proliferación celular o en ladiferenciación celular
JP7662531B2 (ja) 2019-03-28 2025-04-15 ダニスコ・ユーエス・インク 改変抗体
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
CA3135430A1 (en) 2019-03-29 2020-10-08 Atarga, Llc Anti fgf23 antibody
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
CN113939273A (zh) 2019-04-03 2022-01-14 哈佛大学校长及研究员协会 用于药物递送的离子液体
WO2020206233A1 (en) 2019-04-04 2020-10-08 Vanderbilt University Therapeutic antibodies for treating lung cancer
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20220016077A (ko) 2019-04-29 2022-02-08 콘포 테라퓨틱스 엔.브이. Gpcr에 결합하는 화합물 및 리간드를 스크리닝하는 키메라 단백질 및 방법
EP3962599A1 (en) 2019-04-30 2022-03-09 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
US20200363400A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Competitive Ligand Binding Assays
EP3969569A1 (en) 2019-05-14 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
CN114245806A (zh) 2019-05-14 2022-03-25 哈普恩治疗公司 EpCAM结合蛋白及使用方法
WO2020229648A1 (en) 2019-05-16 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
EP3978532A4 (en) 2019-05-24 2023-10-18 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
GB2584441A (en) 2019-06-03 2020-12-09 Fenomark Diagnostics Ab Medical uses, methods and uses
US20220242968A1 (en) 2019-06-04 2022-08-04 Biotheus Inc. Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof
JOP20210326A1 (ar) 2019-06-12 2023-01-30 Novartis Ag أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
KR20220044939A (ko) 2019-06-17 2022-04-12 비스테라, 인크. Cd138에 대한 인간화 항체 분자 및 이의 용도
US20220259295A1 (en) 2019-06-20 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method useful in tolerance induction therapy and kits therefore
KR20220064953A (ko) 2019-06-21 2022-05-19 소리소 파마슈티컬스 인크. 폴리펩티드
CN114555643B (zh) 2019-06-21 2025-02-18 索瑞索制药公司 组合物
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20230061378A1 (en) 2019-07-01 2023-03-02 Suzhou Alphamab Co., Ltd. Pertussis toxin binding protein
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
US12435143B2 (en) 2019-07-15 2025-10-07 Intervet Inc. Caninized antibodies against canine CTLA-4
BR112022001415A2 (pt) 2019-07-26 2022-06-07 Visterra Inc Agentes interleucina-2 e os usos dos mesmos
EP4010079A1 (en) 2019-08-05 2022-06-15 Stichting VU Identification and elimination of hcmv-infected cells
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
AR119887A1 (es) 2019-09-04 2022-01-19 Genentech Inc Agentes de unión a cd8 y sus usos
EP4025712A1 (en) 2019-09-05 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Method of treatment and pronostic of acute myeloid leukemia
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
JP2022548484A (ja) 2019-09-16 2022-11-21 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ３９抗体の組成物及び方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP2022549854A (ja) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
US20220290151A1 (en) 2019-09-27 2022-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
TW202126295A (zh) 2019-09-27 2021-07-16 大陸商江蘇挪貝肽醫藥科技有限公司 一種治療心境障礙的方法
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
EP4048285A1 (en) 2019-10-21 2022-08-31 Novartis AG Tim-3 inhibitors and uses thereof
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
EP4048703A1 (en) 2019-10-21 2022-08-31 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
US20230002785A1 (en) 2019-10-28 2023-01-05 Georgia Tech Research Corporation Mrna-encoded antibodies for contraception
US20240148901A1 (en) 2019-10-28 2024-05-09 Georgia Tech Research Corporation Compositions and methods for prophylaxis of hiv
CN115697387A (zh) 2019-11-05 2023-02-03 细胞基因公司 抗bcma嵌合抗原受体的用途
WO2021095031A2 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
CA3177479A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
IL293145A (en) 2019-11-22 2022-07-01 Harvard College Ionic liquids for drug delivery
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
JP2023504733A (ja) 2019-12-05 2023-02-06 オーエスイー・イミュノセラピューティクス 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
BR112022010231A2 (pt) 2019-12-06 2022-09-06 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
TWI861302B (zh) 2019-12-09 2024-11-11 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
IL294045A (en) 2019-12-20 2022-08-01 Hudson Inst Med Res Proteins that bind to cxcl10 and their uses
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
EP4076525A4 (en) 2019-12-20 2024-05-01 Momenta Pharmaceuticals, Inc. ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US20230076670A1 (en) 2020-01-17 2023-03-09 Universiteit Gent Immunoglobulin single domain antibodies for delivery of mucosal vaccines
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
EP4110794A1 (en) 2020-02-25 2023-01-04 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW202146441A (zh) 2020-02-27 2021-12-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
WO2021183675A2 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP7765397B2 (ja) 2020-03-12 2025-11-06 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規抗ｌｉｌｒｂ４抗体および派生産物
JP7705873B2 (ja) 2020-03-13 2025-07-10 江蘇恒瑞医薬股▲ふん▼有限公司 Ｐｖｒｉｇ結合タンパク質及びその医薬用途
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
JP7732996B2 (ja) 2020-03-20 2025-09-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ポリソルベートを検出する方法
EP4126241A1 (en) 2020-03-27 2023-02-08 Novartis AG Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
JP2023519967A (ja) 2020-03-30 2023-05-15 アブリンクス・エヌ・フェー 多価免疫グロブリン単一可変ドメインの製造及び精製のための方法
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
CN121100948A (zh) 2020-03-31 2025-12-12 生物催化公司 抗真菌多肽
AU2021248643A1 (en) 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
AU2021257848A1 (en) 2020-04-15 2022-12-01 Voyager Therapeutics, Inc. Tau binding compounds
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法
CN113527488A (zh) 2020-04-22 2021-10-22 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7765090B2 (ja) 2020-05-01 2025-11-06 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ナノボディ及びナノボディ親和性を同定するための組成物及び方法
MX2022013876A (es) 2020-05-04 2023-02-09 Immunorizon Ltd Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
EP4424711A3 (en) 2020-05-19 2024-10-23 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
EP3916088A1 (en) 2020-05-28 2021-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
EP4157923A2 (en) 2020-05-29 2023-04-05 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
CN111647077B (zh) 2020-06-02 2021-02-09 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CN116157510A (zh) 2020-06-17 2023-05-23 詹森生物科技公司 用于制造多能干细胞的材料和方法
US20230218608A1 (en) 2020-06-18 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
JP2023531722A (ja) 2020-06-24 2023-07-25 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
CA3187283A1 (en) 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022006219A2 (en) 2020-07-02 2022-01-06 Trustees Of Tufts College Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
WO2022002233A1 (zh) 2020-07-03 2022-01-06 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CR20230009A (es) 2020-07-16 2023-01-25 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
CN113956357B (zh) 2020-07-21 2024-02-20 苏州智核生物医药科技有限公司 Cd8结合多肽及其用途
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
US20240279595A1 (en) 2020-07-31 2024-08-22 Biotalys NV Expression host
UY39373A (es) 2020-08-10 2022-02-25 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
EP4204458A4 (en) 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022056497A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Single domain antibodies against cd33
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
EP4214235A1 (en) 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
BR112023005273A2 (pt) 2020-09-25 2023-04-25 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
IL302068A (en) 2020-10-14 2023-06-01 Viridian Therapeutics Inc Preparations and methods for treating eye disease of the thyroid gland
EP4232064A1 (en) 2020-10-21 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) C-terminal sparc fragments for treating cancer
US20220119536A1 (en) 2020-10-21 2022-04-21 Boehringer Ingelheim International Gmbh Agonistic trkb binding molecules for the treatment of eye diseases
US20230398149A1 (en) 2020-11-04 2023-12-14 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
CN116390933A (zh) 2020-11-06 2023-07-04 诺华股份有限公司 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024502708A (ja) 2020-12-04 2024-01-23 ビステラ， インコーポレイテッド インターロイキン－２作用物質を使用する方法
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
JP2023552773A (ja) 2020-12-04 2023-12-19 セルジーン コーポレーション 炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
IL303745A (en) 2020-12-17 2023-08-01 Ose Immunotherapeutics Bifunctional anti-pd1/il-7 molecules
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
TW202241948A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 基於TCR α/β反應性的T細胞募集多肽
AU2021399955A1 (en) 2020-12-18 2023-08-03 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
JP2024503506A (ja) 2021-01-20 2024-01-25 ビステラ， インコーポレイテッド インターロイキン－２変異体およびその使用
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4303233A4 (en) 2021-02-01 2025-05-07 St Phi Therapeutics Co., Ltd. Targeted protein degradation system and use thereof
AU2022217812A1 (en) 2021-02-05 2023-08-03 Salubris Biotherapeutics, Inc. Il-15 fusion proteins and methods of making and using same
JP2024506020A (ja) 2021-02-05 2024-02-08 ブイアイビー ブイゼットダブリュ サルベコウイルス結合剤
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
US20240229154A9 (en) 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
EP4294407A1 (en) 2021-02-17 2023-12-27 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2022177392A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Cd47에 대한 단일 도메인 항체 및 이의 용도
WO2022177393A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
WO2022177394A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
GB202104104D0 (en) 2021-03-24 2021-05-05 Liliumx Ltd Platform and method
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4320227A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
US20240369570A1 (en) 2021-04-09 2024-11-07 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240190993A1 (en) 2021-04-14 2024-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
EP4322991A1 (en) 2021-04-16 2024-02-21 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
WO2022235628A1 (en) 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
EP4334348A1 (en) 2021-05-07 2024-03-13 Surface Oncology, LLC Anti-il-27 antibodies and uses thereof
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
WO2022246154A2 (en) 2021-05-20 2022-11-24 Dianthus Therapeutics, Inc. Antibodies that bind to c1s and uses thereof
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
AU2021451307A1 (en) 2021-06-16 2024-02-01 Shanghai Sinobay Biotechnology Co., Ltd. Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
CA3224912A1 (en) 2021-06-22 2022-12-29 Merck Patent Gmbh Vhh-based nkp30 binders
WO2022268993A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
CN114230665B (zh) 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
EP4365199A4 (en) 2021-06-29 2025-02-26 Shandong Simcere Biopharmaceutical Co., Ltd. Cd16 antibody and use thereof
US20240382628A1 (en) 2021-07-15 2024-11-21 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
JP2024530455A (ja) 2021-07-30 2024-08-21 ブイアイビー ブイゼットダブリュ 標的化タンパク質の分解のためのカチオン非依存性マンノース６リン酸受容体結合体
EP4380691A1 (en) 2021-08-06 2024-06-12 Institut Régional du Cancer de Montpellier (ICM) Methods for the treatment of cancer
US20230084477A1 (en) 2021-08-10 2023-03-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
CA3228641A1 (en) 2021-08-24 2023-03-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fap/cd40 binding molecule and medicinal use thereof
WO2023041985A2 (en) 2021-09-15 2023-03-23 New York University In Abu Dhabicorporation Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
US20240376207A1 (en) 2021-09-15 2024-11-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
TW202328195A (zh) 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｄ－１的蛋白及其醫藥用途
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
IL311885A (en) 2021-10-08 2024-06-01 Harvard College Ionic liquids for drug delivery
CA3234995A1 (en) 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
EP4177266A1 (en) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
WO2023079137A1 (en) 2021-11-05 2023-05-11 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
US20250026839A1 (en) 2021-11-09 2025-01-23 Ose Immunotherapeutics Identification of CLEC-1 Ligand and Uses Thereof
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
EP4180518A1 (en) 2021-11-12 2023-05-17 Istituto Europeo di Oncologia S.r.l. T cells and uses thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4433089A1 (en) 2021-11-19 2024-09-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
EP4437547A1 (en) 2021-11-22 2024-10-02 Ablynx N.V. Obtaining sequence information for target multivalent immunoglobulin single variable domains
EP4436982A1 (en) 2021-11-24 2024-10-02 Novartis AG Modulators of adeno-associated virus transduction and uses thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
TW202330596A (zh) 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 經修飾的蛋白或多肽
WO2023098637A1 (zh) 2021-11-30 2023-06-08 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
CN118696058A (zh) 2021-12-03 2024-09-24 山东先声生物制药有限公司 抗bcma纳米抗体及其应用
KR20240142411A (ko) 2021-12-15 2024-09-30 인테리우스 바이오테라퓨틱스, 인코포레이티드 위형 바이러스 입자, 이를 포함하는 조성물 및 이의 용도
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
US20250145705A1 (en) 2021-12-31 2025-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Gprc5d antibody and application thereof
EP4209508A1 (en) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanobodies for the deneddylating enzyme nedp1
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
KR20240137086A (ko) 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
US20250129387A1 (en) 2022-02-02 2025-04-24 Biotalys NV Methods for genome editing
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
EP4476250A1 (en) 2022-02-07 2024-12-18 Vib Vzw Engineered stabilizing aglycosylated fc-regions
CN118660972A (zh) 2022-02-11 2024-09-17 汉高股份有限及两合公司 用于合成α-亚甲基-γ-丁内酯的方法
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
EP4496583A1 (en) 2022-03-23 2025-01-29 Bodhi Bio LLC Antigen-specific therapy for autoimmune diseases
CA3254560A1 (en) 2022-03-30 2023-10-05 Novartis Ag METHODS OF TREATMENT OF DISORDERS USING ANTI-NATRIURETIC PEPTIDE RECEPTOR 1 (NPR1) ANTIBODIES
CN119487069A (zh) 2022-04-11 2025-02-18 Vor生物制药股份有限公司 结合剂及其使用方法
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
JP2025512483A (ja) 2022-04-13 2025-04-17 オーエスイー・イミュノセラピューティクス 抗体を選択的に排除するための分子の新規のクラス
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
AU2023262513A1 (en) 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof
EP4514390A1 (en) 2022-04-28 2025-03-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
KR20250009454A (ko) 2022-05-07 2025-01-17 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도
US20250223326A1 (en) 2022-05-10 2025-07-10 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
IL316892A (en) 2022-05-11 2025-01-01 Regeneron Pharma Multispecific proprotein binding molecules and their uses
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023221936A1 (zh) 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
IL316708A (en) 2022-05-18 2024-12-01 Vib Vzw Cerbevirus S2 spike subunit binding
US20230372395A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
KR20230163305A (ko) 2022-05-19 2023-11-30 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
JP2025518164A (ja) 2022-05-30 2025-06-12 オセ イムノセラピューティクス Ｉｌ７ｒモジュレーター活性のバイオマーカー
WO2023232036A1 (zh) 2022-05-31 2023-12-07 明济生物制药（北京）有限公司 抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用
AU2023283519A1 (en) 2022-06-06 2025-01-09 Shandong Simcere Biopharmaceutical Co., Ltd. Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
IL317461A (en) 2022-06-08 2025-02-01 Tidal Therapeutics Inc Ionized Cationic Lipids and Lipid Nanoparticles and Methods of Synthesis and Use thereof
JP2025530888A (ja) 2022-06-14 2025-09-18 アブリンクス エン．ヴェー． Ｔ細胞レセプターを標的とするイムノグロブリン単一可変ドメイン
EP4299124A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 nanobodies for use as biomolecule transporter
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
EP4299125A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 biparatopic nanobodies and uses thereof
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
AU2023303873A1 (en) 2022-07-08 2025-01-02 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
KR102749341B1 (ko) 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
AU2023305094A1 (en) 2022-07-15 2025-01-16 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
JP2025525566A (ja) 2022-07-18 2025-08-05 アブリンクス エン．ヴェー． Ｃｘ３ｃｒ１結合化合物、その使用及び関連する方法
JP2025525612A (ja) 2022-07-22 2025-08-05 ヤンセン バイオテツク，インコーポレーテツド エフェクター免疫細胞への遺伝的命令の増強された移入
EP4562155A2 (en) 2022-07-25 2025-06-04 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
TW202423965A (zh) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
CN119855827A (zh) 2022-08-01 2025-04-18 Ose免疫疗法公司 异源二聚Fc-CLEC-1融合分子及其用途
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
JP2025528068A (ja) 2022-08-03 2025-08-26 ボイジャー セラピューティクス インコーポレイテッド 血液脳関門を通過させるための組成物及び方法
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
AU2023330110A1 (en) 2022-08-22 2025-03-06 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
EP4580658A1 (en) 2022-08-31 2025-07-09 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
TW202417490A (zh) 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
JP2025529318A (ja) 2022-09-06 2025-09-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を有する患者における診断及び予後バイオマーカプロファイル
EP4584299A2 (en) 2022-09-07 2025-07-16 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
EP4584292A1 (en) 2022-09-09 2025-07-16 Yale University Proteolysis targeting antibodies and methods of use thereof
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
EP4587470A1 (en) 2022-09-15 2025-07-23 Voyager Therapeutics, Inc. Tau binding compounds
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
WO2024069180A2 (en) 2022-09-28 2024-04-04 LiliumX Ltd. Multivalent proteins and screening methods
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
CN120322456A (zh) 2022-10-28 2025-07-15 嘉和生物药业有限公司 新型抗ctla4抗体
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
JP2025537215A (ja) 2022-11-02 2025-11-14 ▲蘇▼州康▲寧▼杰瑞生物科技有限公司 Ｇｉｐｒ結合タンパク質及びその使用
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
CN120584135A (zh) 2022-11-10 2025-09-02 英姆维亚公司 结合dr5和muc16的细胞毒性双特异性抗体及其用途
CN120379763A (zh) 2022-11-15 2025-07-25 Imec 非营利协会 用于液滴操控的方法和系统
IL320903A (en) 2022-11-21 2025-07-01 Dianthus Therapeutics Opco Inc Antibodies that bind to C1S and their uses
TW202421667A (zh) 2022-11-29 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
US12049502B2 (en) 2022-11-30 2024-07-30 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN120615013A (zh) 2022-12-01 2025-09-09 世代生物公司 用于细胞靶向的隐形脂质纳米颗粒组合物
WO2024123963A2 (en) 2022-12-07 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024126363A1 (en) 2022-12-12 2024-06-20 Institut National de la Santé et de la Recherche Médicale Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
AU2023394987A1 (en) 2022-12-15 2025-06-26 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
AU2023410327A1 (en) 2022-12-19 2025-06-05 Umc Utrecht Holding B.V. Btn2a1 binding peptide
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
EP4638502A2 (en) 2022-12-21 2025-10-29 Genzyme Corporation Anti-pd-1×4-1bb binding proteins
US20250382652A1 (en) 2022-12-22 2025-12-18 Biotalys NV Methods for genome editing
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
TW202440159A (zh) 2022-12-29 2024-10-16 大陸商蘇州創勝醫藥集團有限公司 含有治療性抗體的藥物製劑及其用途
WO2024145551A1 (en) 2022-12-29 2024-07-04 Biotalys NV Agrochemical compositions
WO2024141638A1 (en) 2022-12-30 2024-07-04 Biotalys NV Self-emulsifiable concentrate
WO2024141641A2 (en) 2022-12-30 2024-07-04 Biotalys NV Secretion signals
WO2024143925A1 (ko) 2022-12-30 2024-07-04 연세대학교 산학협력단 Rnase a에 특이적으로 결합하는 항체 또는 펩티드, 및 rnase a 검출 면역분석 장치 및 방법 그리고 rnase a 포집 방법
EP4642233A1 (en) 2022-12-30 2025-11-05 Biotalys NV Agglomerate
WO2024149237A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
EP4648792A2 (en) 2023-01-09 2025-11-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
KR20250148746A (ko) 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
IL322269A (en) 2023-02-06 2025-09-01 Merck Patent Gmbh VHH-based NKP46 binding agents
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
CN121013866A (zh) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2024175031A1 (zh) 2023-02-21 2024-08-29 江苏恒瑞医药股份有限公司 Il-36r结合蛋白及其医药用途
TW202434296A (zh) 2023-02-24 2024-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種ｆａｐ／ｃｄ４０結合分子的醫藥組成物及其醫藥用途
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
EP4674868A1 (en) 2023-03-01 2026-01-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fap/4-1bb/cd40 binding molecule and medicinal use thereof
TW202436354A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗cldn6抗體以及其使用方法
AR132063A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AR132062A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cd3 y métodos de uso
CN120858176A (zh) 2023-03-07 2025-10-28 居里研究所 Brca相关癌症中的ung/udg抑制
EP4676453A1 (en) 2023-03-08 2026-01-14 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
US20240344078A1 (en) 2023-03-14 2024-10-17 Aarhus Universitet Genetically altered nfr5 receptor kinases
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
EP4681729A1 (en) 2023-03-15 2026-01-21 Shanghai Mabgen Biotech Ltd. Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
EP4683630A1 (en) 2023-03-21 2026-01-28 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
CN120958023A (zh) 2023-03-24 2025-11-14 赛诺菲 通过阻断il-13和tslp治疗哮喘
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
KR20250173521A (ko) 2023-03-30 2025-12-10 272바이오 리미티드 GnRH-결합 폴리펩티드 및 그의 용도
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024224323A1 (en) 2023-04-24 2024-10-31 King Abdullah University Of Science Of Technology Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
CN121079319A (zh) 2023-05-08 2025-12-05 赛诺菲 免疫球蛋白单可变结构域的糖基化
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024238565A1 (en) 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2024238790A1 (en) 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
CN121443743A (zh) 2023-05-23 2026-01-30 赛纳生物技术公司 串联融合剂和相关脂质颗粒
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251783A1 (en) 2023-06-05 2024-12-12 Sanofi Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
WO2024251983A1 (en) 2023-06-09 2024-12-12 Merck Patent Gmbh Il-18 mimetics
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2024261338A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Immunoglobulin single variable domains targeting pd-l1
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease
WO2025024645A1 (en) 2023-07-25 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rapid method for producing antibodies
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025032213A1 (en) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025078418A1 (en) 2023-10-10 2025-04-17 Nano Tag Biotechnologies Gmbh Humanized single-domain antibodies binding to epitope tags
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
AR134082A1 (es) 2023-10-11 2025-12-03 BioNTech SE Agentes y métodos para la administración dirigida de células efectoras inmunitarias
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025132833A1 (en) 2023-12-20 2025-06-26 Institut National de la Santé et de la Recherche Médicale Anti trypsin-3 single domain antibody
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
EP4574981A1 (en) 2023-12-22 2025-06-25 Biotalys NV Anti-fungal vhh antibodies
WO2025133252A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Immunoglobulin single variable domains targeting ceacam5
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025160546A1 (en) 2024-01-26 2025-07-31 The Johns Hopkins University Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
AU2024427245A1 (en) 2024-02-05 2026-01-22 Regenecore Biotech Co., Ltd Anti-cd33 single-domain antibody, anti-cd123 antibody, polypeptide targeting cd33 and cd123 molecules, and use thereof
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025231143A1 (en) 2024-04-30 2025-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against ev-d68
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238157A1 (en) 2024-05-15 2025-11-20 Katholieke Universiteit Leuven Multispecific binding agent suitable for use in cancer immune therapy
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025257408A1 (en) 2024-06-14 2025-12-18 Sanofi Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026002934A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Combination of a slc16a1 inhibitor and a smad3 inhibitor for treating cancer
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026003239A2 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Method to improve macrophages functions
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026008785A1 (en) 2024-07-03 2026-01-08 Biotalys NV Agrochemical compositions
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISR. JOUR. VET. MED., VOL 43, NO 3, 1987, PP 198-203 *
NATURE, VOL 341, 12 OCTOBER 1989, PP 544-546 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide

Also Published As

Publication number Publication date
ATE420178T1 (de) 2009-01-15
JP3444885B2 (ja) 2003-09-08
DE69330523T4 (de) 2012-08-23
EP1498427B1 (en) 2009-12-16
FI20041584L (fi) 2004-12-08
ES2338791T3 (es) 2010-05-12
JP2005170953A (ja) 2005-06-30
EP1589107A1 (en) 2005-10-26
EP1621554A1 (en) 2006-02-01
DE69334308D1 (de) 2010-02-04
EP1621554B2 (en) 2012-08-29
DE69330523T3 (de) 2010-10-28
DK1589107T3 (da) 2010-04-26
PT1498427E (pt) 2010-03-22
EP1087013A3 (en) 2001-11-28
DE69330523T2 (de) 2002-03-28
ES2325541T3 (es) 2009-09-08
EP0656946B2 (en) 2010-03-31
FI950782A0 (fi) 1995-02-20
EP2192131A1 (en) 2010-06-02
ATE452207T1 (de) 2010-01-15
EP1621554B1 (en) 2009-04-08
PT1589107E (pt) 2010-03-29
EP1498427A1 (en) 2005-01-19
PT1621554E (pt) 2009-07-13
ATE203767T1 (de) 2001-08-15
PT656946E (pt) 2001-12-28
FI950782A7 (fi) 1995-04-20
FI120404B (fi) 2009-10-15
US6015695A (en) 2000-01-18
ES2338321T3 (es) 2010-05-06
CA2142331C (en) 2010-02-02
JP2002053600A (ja) 2002-02-19
US5874541A (en) 1999-02-23
DE69334258D1 (de) 2009-02-26
JP2009280608A (ja) 2009-12-03
FI20070170L (fi) 2007-02-28
EP1589107B1 (en) 2009-12-23
ES2322324T3 (es) 2009-06-19
ES2162823T3 (es) 2002-01-16
EP0656946A1 (en) 1995-06-14
DE69334275D1 (de) 2009-05-20
DK1087013T3 (da) 2009-05-11
JP3660270B2 (ja) 2005-06-15
US5840526A (en) 1998-11-24
EP1087013B1 (en) 2009-01-07
DK1621554T4 (da) 2012-12-17
GR3037024T3 (en) 2002-01-31
PT1087013E (pt) 2009-04-15
ATE452975T1 (de) 2010-01-15
ATE427968T1 (de) 2009-04-15
JPH08500487A (ja) 1996-01-23
FI117975B (fi) 2007-05-15
DE69330523D1 (de) 2001-09-06
US5759808A (en) 1998-06-02
DK1498427T3 (da) 2010-04-26
DE69334305D1 (de) 2010-01-28
EP0656946B1 (en) 2001-08-01
DK0656946T4 (da) 2010-07-26
DK0656946T3 (da) 2001-11-05
JP4414900B2 (ja) 2010-02-10
WO1994004678A1 (en) 1994-03-03
US5800988A (en) 1998-09-01
ES2162823T5 (es) 2010-08-09
AU4949793A (en) 1994-03-15
FI115462B (fi) 2005-05-13
CA2142331A1 (en) 1994-03-03
DK1621554T3 (da) 2009-08-10
EP1087013A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
AU701578B2 (en) Immunoglobulins devoid of light chains
US7722871B2 (en) Immunoglobulins devoid of light chains
US6005079A (en) Immunoglobulins devoid of light chains
EP0584421A1 (en) Immunoglobulins devoid of light chains
AU738133B2 (en) Immunoglobulins devoid of light chains
HK1074450A (en) Immunoglobulins devoid of light chains